chir-258
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2010 (NCT00831792)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Fibroblast growth factor receptor 1INHIBITOR
FGFR1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1- Mol. weight
- 392.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL522892 ↗
- ChEMBLCHEMBL2103806 ↗
Also known as
- chir-258
- chir-258
- tk1258
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00831792 | Phase 2 | Apr 1, 2010 | Novartis, University of Texas at Houston |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 1 | 0 | 1 | 2010 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2010 |
2 organizations
Page 1 / 1